Pathology and Cell Biology
USF Health - College of Medicine
Login here to update your profile  
My Profile

Xiaohong Zhang , M.S., Ph.D.

Primary Department: COLLEGE OF MEDICINE PATHOLOGY & CELL BIOLOGY

Assistant Professor
DEPARTMENT OF ONCOLOGIC SCIENCES

Assoc Professor
COLLEGE OF MEDICINE PATHOLOGY & CELL BIOLOGY
profile Image
Contacts
Email: xzhang1@health.usf.edu
Phone: (813) 974-1288
Office: MDC, 3034
Mailing address 12901 Bruce B. Downs Blvd. ,MDC 11
Tampa, FL 33612
View My C.V.
 
Education
  • PHD, Molecular Biology, University Of Texas Health Science Center At Houston , Houston, United States - 1998.
    		•
  • B.S., Biology, Beijing Normal University , Beijing, Republic of China - 1989.
    		•
     
    Interdisciplinary & Emerging Signature Programs
    Cancer Biology.
     
    Research Summary

    Posttranslational modifications, such as phosphorylation and acetylation, play important roles in a variety of cellular processes. Alterations of these modifications may lead to human diseases including cancer. Our lab is interested in how these posttranslational modifications, particularly acetylation, influence biological functions such as gene expression, cell motility etc., in normal and aberrant settings with an emphasis on histone/protein deacetylases (HDACs). Our ultimate goal is to apply our knowledge to cure human diseases.

    Basic research:

    Current studies in our lab focus on one of the class II HDACs, HDAC6. HDAC6 is unique within the HDAC family. It has two HDAC domains and deacetylates both histone and tubulin, suggesting it plays important roles in both nuclei and cytoplasm. To study the function of HDAC6 systematically, we plan to purify HDAC6 complex from nuclei and cytoplasm. The outcome of this study will reveal the biological functions of this HDAC. In addition, we also set out to investigate how HDAC6s enzymatic activities are regulated by upstream signaling.

    Translational research:

    Our lab is interested in studying role of HDAC6 and its novel substrate, cortactin, in human cancers, particularly in ovarian and breast cancers. Recently, my lab discovered that SIRT1, a class III HDAC, also deacetylates cortactin and is associated with cell migration. We will further determine whether HDAC6, SIRT1 and cortactin, especially the deacetylated form of cortactin, are involved in ovarian and breast cancer metastasis.
     


    Selected Publications
  • Cheung, P. H., Luo, W., Qiu, Y., Zhang, X., Earley, K., Millirons, P., and Lin, S. H. Structure and function of C-CAM1. The first immunoglobulin domain is required for intercellular adhesion. . J Biol Chem. (268): 24303-24310, 1993.
  • Fraizer, G. C., Patmasiriwat, P., Zhang, X., and Saunders, G. F. Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow. Blood. (86): 4704-4706, 1995.
  • Zhang, X., Xing, G., Fraizer, G. C., and Saunders, G. F. ). Transactivation of an intronic hematopoietic-specific enhancer of the human Wilms' tumor 1 gene by GATA-1 and c-Myb. J Biol Chem . (272): 29272-29280, 1997.
  • Fraizer, G. C., Shimamura, R., Zhang, X., and Saunders, G. F. PAX 8 regulates human WT1 transcription through a novel DNA binding site. J Biol Chem . (272): 30678-30687, 1997.
  • Zhang, X., Xing, G., and Saunders, G. F. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1 Anticancer Res . (19): 1641-1648, 1999.
  • Zhang, X.Wharton, W.Donovan, M.Coppola, D.Croxton, R.Cress, WD.Pledger, WJ. Density-dependent growth inhibition of fibroblasts ectopically expressing p27(kip1). Molecular biology of the cell. 11(6): 2117-30, 2000.
  • Hu, X.Zhang, X.Zhong, Q.Fisher, AB.Bryington, M.Zuckerman, KS. Differential effects of transforming growth factor on cell cycle regulatory molecules in human myeloid leukemia cells. Oncogene. 20(47): 6840-50, 2001.
  • Hu, X.Bryington, M.Fisher, AB.Liang, X.Zhang, X.Cui, D.Datta, I.Zuckerman, KS. Ubiquitin/proteasome-dependent degradation of D-type cyclins is linked to tumor necrosis factor-induced cell cycle arrest. The Journal of biological chemistry. 277(19): 16528-37, 2002.
  • Rezai-Zadeh, N.Zhang, X.Namour, F.Fejer, G.Wen, YD.Yao, YL.Gyory, I.Wright, K.Seto, E. Targeted recruitment of a histone H4-specific methyltransferase by the transcription factor YY1. Genes & development. 17(8): 1019-29, 2003.
  • Zhang, X.Ma, L.Enkemann, SA.Pledger, WJ. Role of Gadd45alpha in the density-dependent G1 arrest induced by p27(Kip1). Oncogene. 22(27): 4166-74, 2003.
  • Weiss, C., Schneider, S., Wagner, E. F., Zhang, X., Seto, E., and Bohmann, D. JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun. EMBO J . 22(): 3686-3695, 2003.
  • Nguyen, N.Zhang, X.Olashaw, N.Seto, E. Molecular cloning and functional characterization of the transcription factor YY2. The Journal of biological chemistry. 279(24): 25927-34, 2004.
  • Zhang, X.Wharton, W.Yuan, Z.Tsai, SC.Olashaw, N.Seto, E. Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Molecular and cellular biology. 24(12): 5106-18, 2004.
  • Li, P.Li, C.Zhao, X.Zhang, X.Nicosia, SV.Bai, W. p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. The Journal of biological chemistry. 279(24): 25260-7, 2004.
  • Zhang, X., Ozawa, Y., Lee H., Wen, Y-D., Tan, T-H, Wadzinski, B.E. and Seto, E. Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4 Genes & Dev. . 19(): 827-839, 2005.
  • Gao Z., Chiao, P., Zhang, X., Zhang, X., Lazer, M., Seto E., Young HA., and Ye J. Coactivators and corepressors of NF-kB in IkB alpha gene promoter. J. Biol. Chem. . (280): 21091-21098, 2005.
  • Glozak, MA., Sengupta N., Zhang, X., and Seto E.( Acetylation and deacetylation of non-histone proteins (review) Gene . (363): 15-23, 2005.
  • Feng, W., Lu, Z., Luo, R. Z., Zhang, X., Seto, E., Liao, W.S.L. and Yu, Y Multiple histone deacetylases (HDACs) repress tumor suppressor gene ARHI in breast cancer. In. J. Cancer . 8(120): 1664-1668, 2007.
  • Gregoire, S., Xiao, L., Nie, J., Zhang, X., Xu, M., Li, J., Wong, J., Seto, E., and Yang, X-J Negative regulation of MEF2-dependent transcription by histone deacetylase 3. Mol. Cell. Biol. . 4(27): 1280-1295, 2007.
  • Yuan, Z.Zhang, X.Sengupta, N.Lane, WS.Seto, E. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Molecular cell. 27(1): 149-62, 2007.
  • Hu, X.Cui, D.Moscinski, LC.Zhang, X.Maccachero, V.Zuckerman, KS. TGFbeta regulates the expression and activities of G2 checkpoint kinases in human myeloid leukemia cells. Cytokine. 37(2): 155-62, 2007.
  • Villagra, A.Ulloa, N.Zhang, X.Yuan, Z.Sotomayor, E.Seto, E. Histone deacetylase 3 down-regulates cholesterol synthesis through repression of lanosterol synthase gene expression. The Journal of biological chemistry. 282(49): 35457-70, 2007.
  • Zhang, X.Yuan, Z.Zhang, Y.Yong, S.Salas-Burgos, A.Koomen, J.Olashaw, N.Parsons, JT.Yang, XJ.Dent, SR.Yao, TP.Lane, WS.Seto, E. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Molecular cell. 27(2): 197-213, 2007.
  • Zhang, Y., Zhang, M., Dong, H., Yong, S., Li, X., Olashaw, N., Kruk, P.A., Cheng, J.Q., Bai, W., Chen, J., Nicosia, S.V., and Zhang, X Deacetylation of Cortacin by SIRT1 Promotes Cell Migration Oncogene . 3(28): 445-600, 2009.
  • Ma, Q., Fu, W., Li, P., Nicosia, S., Jenster, G., Zhang, X., and Bai, W. Repression of Androgen Receptor N- and C-Terminal Interaction and Coactivator Recruitment by FoxO1 and its Involvement in Receptor Suppression by the PTEN Tumor Suppressor Mol. Endocrinology . 2(23): 213-225, 2009.
  • Zhang, Y., Dong, H., Li, Z., Xiang, S., Zhu, Y., Zhang, M., Liu, J., Bai, W., Nicosia, S., Chen, J., Zhao, R-J and Zhang, X Bing De Ling®, a Chinese herbal formula, induces G1/S arrest in cancer cells via p53 Frontiers in Bioscience (accepted) . (): , 2009.
  • Li P, Wang D, Yao H, Doret P, Hao G, Shen Q, Wiu H, Zhang X, Wang Y, Chen G, and Wang Y. Coordination of PAD4 and HDAC2 in the regulation of p53 target gene expression Oncogene. (): 3153, 2010.

    • Positions Held
  • Assistant Professor (Department Pathology and Cell Biology, College of Medicine, University of South Florida 2006 - Present)
  • Research Scientist (Interdisciplinary Oncology Program, College of Medicine, University of South Florida 2004 - 2006)
  • Instructor (Interdisciplinary Oncology Program, College of Medicine, H.Lee Moffitt Cancer Center at University of South Florida 2002 - 2004)
  • Research Associate (Interdisciplinary Oncology Program, College of Medicine, H. Lee Moffitt Cancer Center at University of South Florida 1998 - 2002)


    • Memberships
  • American Association for Cancer Research (AACR) (Member, 2006 - Present)
  • American Association for the Advancement of Science (AAAS) (Member, 2001 - Present)
  • American Society for Cell Biology (Member, 2000 - 2006)


    • Awards/Honors
  • Liz Tilberis Scholar (Ovarian Cancer Research Fund - 2011)
    		•
  • Marsha Rivkin Scholar ( Marsha Rivkin Center for Ovarain Cancer Research - 2007)
    		•


    Grants
  • ROLE OF HDAC6 IN PLATINUM RESISTANCE OF NON-SMALL CELL LUNG CANCER ($143,387.00, 05/01/2012-03/31/2017)
  • ROLE OF HDAC6 IN PLATINUM RESISTANCE OF NON-SMALL CELL LUNG CANCER ($339,386.00, 05/01/2012-03/31/2017)
  • MECHANISMS BY WHICH HDAC INHIBITORS REGULATE CISPLATIN SENSITIVITY IN OVARIAN CANCER ($150,000.00, 06/01/2011-05/31/2014)
  • MECHANISMS BY WHICH HDAC INHIBITORS REGULATE CISPLATIN SENSITIVITY IN OVARIAN CANCER ($150,000.00, 06/01/2011-05/31/2014)
  • MECHANISMS BY WHICH HDAC INHIBITORS REGULATE CISPLATIN SENSITIVITY IN OVARIAN CANCER ($150,000.00, 06/01/2011-05/31/2014)
  • MECHANISMS BY WHICH HDAC6 CONFERS CHEMORESISTANCE IN LUNG CANCER ($125,000.00, 10/01/2009-12/31/2012)
  • MECHANISMS BY WHICH HDAC6 CONFERS CHEMORESISTANCE IN LUNG CANCER ($125,000.00, 10/01/2009-06/30/2012)
  • MECHANISMS BY WHICH HDAC6 CONFERS CHEMORESISTANCE IN LUNG CANCER ($125,000.00, 10/01/2009-06/30/2012)
  • ROLE OF HISTONE DEACETYLAS 6 AND 53 IN CISPLATIN RESISTANCE OF LUNG CANCER ($50,000.00, 11/01/2009-10/31/2011)
  • MECHANISMS BY WHICH HDAC INHIBITORS SENSITIZE THE CISPLATIN RESISTANT OVARIAN CELLS ($75,000.00, 05/01/2009-01/31/2011)
  • HDAC6 DEACETYLATION OF CORTACTIN IN EGF-INDUCED BREAST CANCER CELL MIGRATION ($125,000.00, 01/17/2008-12/31/2010)
  • ROLE OF HISTONE DEACETYLAS 6 AND 53 IN CISPLATIN RESISTANCE OF LUNG CANCER ($50,000.00, 11/01/2009-10/31/2010)
  • HDAC6 DEACETYLATION OF CORTACTIN IN EGF-INDUCED BREAST CANCER CELL MIGRATION ($125,000.00, 01/17/2008-06/30/2010)
  • HDAC6 DEACETYLATION OF CORTACTIN IN EGF-INDUCED BREAST CANCER CELL MIGRATION ($125,000.00, 01/17/2008-06/30/2010)
  • SUPPRESSION OF EPITHELIAL MESENCHYMAL TRANSITION AND INVASIVE GROWTH OF OVARIAN CANCER CELLS BY A NOVEL HDAC INHIBITOR VORINOSTAT ($48,000.00, 09/07/2007-09/06/2008)
  • ROLE OF HDAC6 AND ITS NOVEL SUBSTRATE CORTACTIN IN OVARIAN CANCER CELL MOTILITY ($30,000.00, 05/01/2007-08/31/2008)


    • Lectures
  • "Vorinostat Study in Cancer Cells and Beyond" Merck/Moffitt Scientific Exchange Day. FL, United States - 2010.
  • "Role of Histone Deacetylases in Human Cancer " Karmanos Cancer Institute. MI, United States - 2010.
  • "Role of histone deacetylase 6 in DNA mismatch repair and chemotherapeutic response" CAS University of South Florida. FL, United States - 2009.
  • "Role of HDAC6 in ovarian cancer cell migration" 7th Biennial Ovarian Symposium, Seattle. WA, United States - 2008.
  • "Deacetylation of cortatin by SIRT1 promotes ovarian and breast cancer cell migration" 5th Anniversary Congress of International Drug Discovery Science and Technology -2007, Xian. People's Republic of China - 2007.
  • "HDAC6 Modulates Cell Motility by Altering the Acetylation Level of Cortactin " FASEB Summer Research Conferences Snowmass Village. CO, United States - 2007.
  • "Department of Medicine" Penn State Cancer Institute . PA, United States - 2005.
  • "Department of Physiology" Tulane University School of Medicine . LA, United States - 2005.
  • "Molecular Mechanisms of Oncogenesis Program" Case Comprehensive Cancer Center. OH, United States - 2005.
  • "Department of Pharmacology & Therapeutics" Roswell Park Cancer Institute . NY, United States - 2005.

    • Profile last modified on 11/06/2012